ever, the relative contribution of these PACAP receptor subtypes to endocrine function remains to be established. In mice, PACAP clearly stimulates insulin secretion, but also inhibits insulin sensitivity, as demonstrated by unaltered glucose disposal during an intravenous glucose tolerance test (11) .
The aim of this study was to investigate the role of PAC1 receptors in insulin secretion and glucose disposal. A mouse strain deficient in PAC1 receptor (PAC1 -/-) was generated by homologous recombination in embryonic stem cells. PAC1 -/-mice were compared with wild-type counterparts for the effects of glucose and PACAP on insulin secretion and glucose tolerance. This work was performed both in vitro in isolated perfused pancreas, and in vivo.
Methods

PAC1 gene targeting.
The intron-exon structure of the gene encoding the PAC1 receptor has already been elucidated (21) . The gene was disrupted by deletion of a 2.3-kb NcoI fragment containing exons 8-11, which was replaced by a pPolII-neomycin selection cassette in the reverse transcription orientation (22) . The targeting vector contained 4.2 kb and 2.8 kb of homologous sequences up-and downstream from the pPolIIneomycin sequence, respectively. An MC1-TK counter selection marker flanked the 3′ homology (23) . The linearized vector was electroporated into mouse embryonic stem cells (129/Sv-derived H1 embryonic stem cells from A. Dierich and P. Chambon, patent LGMEu184, Strasbourg, France). Targeted clones were screened for 2 weeks with 180 µg/mL geneticin (G418; Life Technologies Inc., Gaithersburg, Maryland, USA) and 2 µM ganciclovir (Cymevan; Syntex, Puteaux, France). DNA extracted from resistant clones was analyzed by Southern blotting with 5′ and 3′ flanking probes for homologous targeting events; five positive clones were confirmed by PCR analysis using primers p7 (5′-TGGGTTTGATGACTATGAGC-3′), p8 (5′-TGAGGGTGACGAGGGAGG TG-3′), and pNeo (5′-GCCTTCTATCGCCTTCTTGA-3′). Clones were injected into blastocysts to produce germline chimeras. An F1 crossbred mouse strain (129/Sv × C57BL6/J) heterozygous for loss of PAC1 was bred to yield wild-type mice and mutants heterozygous and homozygous for loss of the PAC1 receptor (PAC1 +/-and PAC1 -/-mice).
Binding experiments. Brain membranes were prepared as described previously (24) . PACAP27 (Neosystem, Strasbourg, France) was iodinated by the iodogen method (21) . Competitive binding was performed by incubating 50 µg of total brain membrane proteins with 50 pM 125 I-PACAP27 and increasing amounts of cold PACAP27 for 60 minutes at 25°C. Experiments were done in triplicate using at least two distinct membrane preparations. Binding data were analyzed using EBDA-Ligand software (Elsevier Biosoft, Cambridge, United Kingdom).
Measurement of cAMP levels in cerebellar granule cells and pancreatic islets. Mice cerebellar granule neurons were prepared from 7-to 8-day-old pups by mechanical dissociation (25) . Cells were plated at 3 × 10 5 cells per cm 2 on poly-L-ornithine; assays for cAMP production were done with 7-day cultures. Cells were incubated with [2-3 H]adenine for 2 hours in serum-free medium, then with 100 µM Ro-20-1724 (Biochem, Meudon, France) for 10 min-utes at 37°C followed by 15 minutes with PACAP27, PACAP38, or VIP (Neosystem). The islets were isolated by collagenase digestion of pancreas dissected from fed 30-to 32-week-old female mice. After loading with [2-3 H] adenine for 90 minutes in a medium containing 10 mM glucose, they were incubated for 30 minutes in batches of 13-15 with 16.7 mM glucose alone, and then for 15 minutes with PACAP38 or VIP in the presence of 250 µM isobutyl methylxanthine. In both experiments, the reaction was stopped by 5% trichloracetic at 4°C. After centrifugation, [2-3 H]cAMP was separated from [2-3 H]ATP and measured as described previously (26) .
Plasma glucose and hormone measurements. Blood samples of conscious mice were drawn from the retrobulbar, intraorbital capillary plexus into heparinized chilled tubes, and were immediately centrifuged at 4°C. Plasma was separated and then stored at -20°C for subsequent determination of glucose, insulin, and glucagon levels. Plasma glucose levels were determined by the glucose oxidase method (Peridochrom Glucose; Roche Diagnostic Systems Inc., Indianapolis, Indiana, USA). Insulin and glucagon concentrations were determined by radioimmunoassay using charcoal separation as described previously (8) .
Pancreatic insulin and glucagon content measurements. Whole pancreata were removed from the mice, and insulin and glucagon were extracted by mechanical homogenization in iced acid ethanol (0.7 mol/L HClethanol; 25:75). After 48 hours at 4°C, hormone concentrations were determined by radioimmunoassay (8) .
In vitro isolated perfused pancreas studies. Experiments were performed with female mice 21-30 weeks of age, fed ad libitum. After anesthesia with sodium pentobarbital (70 mg/kg), the pancreas was totally isolated from all neighboring tissues according to the surgical procedure for the rat pancreas described previously (27) . The pancreas was then perfused through its own arterial system with KrebsRinger bicarbonate buffer. The preparation was maintained at 37.5°C. Each organ was perfused at a constant flow rate of 1 mL/min during a 30-minute stabilization period. The flow rate was measured during 1 minute for each sample, which was immediately frozen for insulin determination. After each perfusion experiment, the pan- creas insulin content was measured (8) . For the kinetics of insulin output, results are expressed as changes in relation to the measured pancreatic insulin content.
Intravenous glucose tolerance test. Female mice fed ad libitum were anesthetized as described previously (11) . D-glucose (1g/kg) was injected rapidly into a tail vein, either alone or together with PACAP27 or VIP. Both peptides were administered at 1.3 nmol/kg, a dose that was shown to maximally activate insulin secretion when given intravenously in normal mice (11) . In one series of experiments, L-arginine (0.25 g/kg) was injected. The volume load was 10 µL/g body wt. Blood samples were drawn into chilled heparinized tubes after 1, 5, 20, and 50 minutes from the retrobulbar, intraorbital capillary plexus. Plasma determinations of glucose and insulin were performed as described previously (11) .
Gastric glucose tolerance test. Mice fasted for 2 hours were anesthetized as above. A blood sample was taken, and Dglucose (150 mg/mouse in 0.5 mL) was administered through a gavage tube placed in the stomach. Blood samples were thereafter taken at 10, 30, 60, and 120 minutes for plasma glucose and insulin determinations.
Data presentation and statistical analysis. Data are presented as mean ± SEM. Statistical significance was assessed by Student's t test for in vitro studies and by the nonparametric Mann-Whitney U test for in vivo studies. Areas under the insulin and glucose curves (AUC insulin and AUC glucose ) were calculated by the trapezoid rule. (Figure 1a ) encodes the mouse PAC1 receptor (21) . To produce a null allele, we exchanged sequences in the targeting vector encoding exons 8-11 with a neomycin selection cassette (Figure 1b) . After homologous recombination, analysis of genomic DNA was performed using Southern blot, PCR, or both ( Figure 1 , c and d) to distinguish the targeted allele from the wild type allele. The targeted allele harbors the neomycin cassette in an intronic region between exons 7 and 12, which is spliced out to generate a truncated mRNA that is detectable by RT-PCR analysis (data not shown). Moreover, this deletion leads to a frame shift with a translation stop codon in exon 12. Therefore, the mutated allele was expected to encode a null receptor. This was demonstrated by several things, including the loss of 90% of the 125 I-PACAP27 binding to PAC1 -/-mouse brain (Figure 2a) , a tissue that in the rat contains 10-fold more PACAP binding sites than VIP binding sites (28) ; and the absence of stimulation by PACAP and VIP of cAMP production in PAC1 -/-cerebellar granule cells (Figure 2b, right panel) . The wildtype counterparts displayed the pharmacological profile of the PAC1 receptor mediating cAMP production ( Figure 2b , left panel). Additionally, there was a dramatic reduction of PACAP38-induced cAMP production in PAC1 -/-pancreatic islets (Figure 2c ), whereas the weak stimulating effect of VIP was not changed.
Results
PAC1 receptor-deficient (PAC1 -/-) mice. An 18-exon gene
A mendelian distribution of pup genotypes from heterozygous mating was observed at birth. However, at weaning, a loss of PAC1 -/-mice became very noticeable, with a genotype distribution of 9%, 59%, and 32% for PAC1 -/-, PAC1 +/-, and wild-type mice, respectively (data not shown). This result indicated a 60% loss of PAC1 -/-pups (χ 2 test, P < 0.005) during the 4 weeks after birth. This mortality remains to be explained. No significant death rate was observed thereafter.
Characteristics of PAC1 -/-mice. This study was conducted on adult female mice 21-30 weeks of age. Table  1 shows various measurements from wild-type and PAC1 -/-mice. The latter exhibit a weak but significant
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The decrease (∼10%) in body weight. Whereas no significant difference was observed in either plasma glucose or plasma glucagon levels, a mild degree of hyperinsulinemia was recorded in conscious, fed PAC1 -/-mice (P < 0.05). This effect was not observed in fasting conditions. Pancreatic insulin and glucagon were at comparable levels in PAC1 -/-pancreas and wild-type pancreas. Thus, the PAC1 receptor did not appear to be essential for either proinsulin or glucagon biosynthesis.
In vitro experiments
Insulin response to glucose. To investigate the glucose sensitivity of β cells in PAC1 -/-mice, we measured the effect of increasing the glucose concentration from 4.2 mmol/L to 16.7 mmol/L, on the insulin secretion from isolated perfused pancreas (Figure 3 ). The glucose stimulation induced an immediate and transient first phase of insulin release, followed by a constant second phase. PAC1 -/-mice displayed a defective insulin response to glucose, particularly during the first phase, when the increment of insulin output over the first 5 minutes was reduced by 55% (P < 0.001) compared with wild-type mice (Figure 3, inset) .
Effects of PACAP and VIP on glucose-induced insulin release. PACAP38 and VIP insulinotropic effects were evaluated from isolated pancreas perfused for 20 minutes with high glucose (Figure 4 ). In the presence of 16.7 mmol/L glucose, 1 nM PACAP38 potentiated insulin secretion, but this effect was about twofold lower in PAC1 -/-mice than in wild-type controls. The increment of insulin output over 20 minutes of peptide infusion was 1.887 ± 0.264% and 3.655 ± 0.646‰ (P < 0.05) of total pancreatic content in PAC1 -/-and wild-type mice, respectively (Figure 4a , inset). In contrast, 1 nM VIP elicited a comparable increase in insulin secretion in PAC1 -/-and control pancreas (3.322 ± 0.808‰ and 3.716 ± 0.740‰ of content; 
In vivo experiments
Intravenous glucose tolerance test. In anesthetized PAC1 -/-mice, after an intravenous injection of glucose (1 g/kg), glucose tolerance and insulin response were significantly impaired ( Figure 5 , left panel). Within 1 minute, the plasma insulin response to glucose was not significantly different among the groups of mice, but the 20-minute (P < 0.05) and 50-minute (P < 0.01) insulin levels, as well as the 50-minute AUC insulin (P < 0.05) were significantly lower in PAC1 -/-mice than in wild-type mice. Simultaneously, the glucose elimination rate was decreased in PAC1 -/-mice. Thus, the 20-(P < 0.05) and 50-minute (P < 0.01) glucose levels and the 50-minute AUC glucose (P < 0.01) were significantly higher in PAC1 -/-mice than in wild-type mice ( Figure 5 , left panel, inset). The impaired insulin response to glucose was also evident when comparing the insulin and glucose data at different timepoints, because the insulinogenic index (the insulin level divided by the glucose level) was lower in PAC1 -/-mice than in wild-type mice both at 20 minutes (7.6 ± 0.3 pmol/mmol vs. 17.7 ± 1.2 pmol/mmol, P < 0.01) and 50 minutes (8.8 ± 0.6 pmol/mmol vs. 26.4 ± 1.9 pmol/mmol, P < 0.001).
In contrast to the impaired insulin response to glucose, the increase in plasma insulin after intravenous administration of arginine was not significantly different between wild-type and PAC1 -/-mice ( Figure 5 , right panel). However, the plasma glucose levels at 20 (P < 0.05) and 50 (P < 0.01) minutes and 50-minute AUC glucose (P < 0.01) were significantly higher in PAC1 -/-mice than in wild-type mice.
Insulin and glucose responses to intravenous PACAP and VIP during an intravenous glucose tolerance test. When PACAP27 (1.3 nmol/kg) was administered intravenously together with glucose, a marked increase of plasma insulin was observed in wild-type mice without any discernible effect on the glucose elimination rate (Figure 6a, left panel) . In PAC1 -/-mice, however, PACAP27 not only potentiated glucose-induced insulin secretion just slightly, but also clearly decreased the glucose elimination rate (Figure 6a, right  panel) . Thus, the 50-minute AUC glucose with PACAP27 stimulation was 0.29 ± 0.04 µmol/L in wild-type mice vs. 0.72 ± 0.05 µmol/L in PAC1 -/-mice (P < 0.001). In contrast, VIP at the same dose (1.3 nmol/kg) exerted a similar stimulatory effect on insulin secretion in PAC1 -/-and wild-type mice (Figure 6b ). However, whereas VIP slightly raised the glucose elimination rate in wild-type mice (the 20-minute glucose value was 17.3 ± 1.2 mmol/L in controls vs. 13.5 ± 1.5 mmol/L after administration of VIP, P < 0.05), it did not improve the impaired glucose elimination in PAC1 -/-mice.
Gastric glucose tolerance test. Administration of glucose (150 mg/mouse) through a gastric tube raised insulin and glucose plasma levels in both wild-type and PAC1 -/-mice ( Figure 7 ). Peak insulin levels were observed at 30 minutes after glucose administration.
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The This glucose-induced insulin increase was markedly reduced in PAC1 -/-mice, both at 10 minutes (P < 0.05) and 30 minutes (P < 0.01). The 120-minute AUC insulin was 44% lower in PAC1 -/-mice than in wild-type mice (P < 0.001). Furthermore, PAC1 -/-mice were markedly glucose intolerant compared with wild-type mice, as judged from elevated 60-minute (P < 0.001) and 120-minute (P < 0.01) glucose levels, and a 55% higher 120-minute AUC glucose (P < 0.01).
Discussion
In this study, we explored a role for the PACAP-preferring receptor, PAC1, in the regulation of insulin secretion and glucose homeostasis using mice lacking this receptor. PAC1 receptor deletion resulted in a decrease of PACAP-induced insulin secretion, clearly demonstrating the functional involvement of this receptor in the insulinotropic action of the peptide. More interestingly, these mice exhibited an impairment of glucose-induced insulin secretion and a reduction in glucose tolerance. This suggests that the presence of the PAC1 receptor is required to maintain normal insulin secretory responsiveness to glucose and glucose homeostasis. Both PAC1 and VPAC2 receptors are expressed in mouse islets (14) . These two receptor subtypes show equal affinity for PACAP, but VIP activates only the VPAC2 receptor (17) . Therefore, our previous findings that PACAP27, PACAP38, and VIP were equipotent in stimulating insulin secretion (8, 14) suggested that the VPAC2 receptor had the most functional importance for the PACAP insulin secretory effect. However, in the isolated perfused pancreas of PAC1 -/-mice, the insulin secretory response to PACAP was reduced by about twofold. This decrease in responsiveness of PACAP in PAC1 -/-mice is probably not related to a change in pancreatic blood flow, because similar vasodilatory responses to PACAP were recorded in PAC1 -/-and wild-type mice. Moreover, this decrease was not associated with a reduction in pancreatic insulin content. In contrast, in PAC1 -/-mice and wild-type mice, VIP potentiated glucose-induced insulin secretion to the same extent. Therefore, these results suggest that PAC1 receptors are quite important for PACAP-induced insulin secretion, and that the remaining insulinotropic action of PACAP observed in vitro in PAC1 -/-pancreas is caused by activation of VPAC2 receptors, which are intact in these mice.
In the isolated perfused pancreas and in vivo, PAC1 -/-mice exhibited a defect in glucose-stimulated insulin release. Two recent studies have reported the inhibition of glucose-stimulated insulin secretion by immunoneutralization of PACAP in freshly isolated rat and mouse islets (10, 20) , suggesting that endogenous PACAP contributes to the insulin secretory response to glucose. Therefore, our data support and extend these previous reports by providing evidence for the involvement of PAC1 receptors in the insulinotropic action of glucose. Moreover, in contrast to glucose, the insulin response to arginine was not impaired in PAC1 -/-mice, showing that the dependence of insulin secretion on the PAC1 receptor is restricted to glucose stimulation and is not a general phenomenon. Although the mechanisms explaining this dependence remain to be studied, one possible explanation could be the fact that cAMP is required for the action of glucose (30) . It is indeed known that PACAP, like the intestinal hormone GLP-1, augments the formation of cAMP (19, 31) and increases the glucose competence of pancreatic β cells (32) . The strong reduction of islet cAMP production by PACAP in PAC1 -/-mice might be a factor in impaired glucose sensing.
The defect in glucose-induced insulin secretion was associated with impaired glucose tolerance in PAC1 -/-mice, consistent with a role for PAC1 in the control of glucose homeostasis. However, these mice exhibit normal glycemia in both the fasted and fed states. Glucose homeostasis results from a balance between insulin secretion and peripheral tissue sensitivity to insulin, although insulin-independent mechanisms also contribute. Because the fed conscious PAC1 -/-mice had higher insulin levels than wild-type mice, it seems possible that, in addition to the defect in insulin secretion, insulin resistance may also participate in the glucose intolerance. In this context, it has been reported that PAC1 receptors are expressed in adipose tissues (33, 34) , 
Figure 7
Gastric glucose tolerance test. Plasma insulin (a) and glucose (b) immediately before and at 10, 30, 60, and 120 minutes after gastric administration of glucose (150 mg/mouse) in 2-hour fasted anesthetized wild-type mice (n = 12) and PAC1 -/-mice (n = 12). Insets are 120-minute AUC insulin and AUC glucose (areas under the 120-minute insulin and glucose curves, respectively), in wild-type mice (open bars) and in PAC1 -/-mice (filled bars). Data are presented as mean ± SEM. A P < 0.05; B P < 0.01; C P < 0.001.
and that PACAP potentiates insulin-stimulated glucose uptake in 3T3 L1 adipocytes (34) . On the other hand, a previous study in normal mice showed that during an intravenous glucose tolerance test, PACAP, despite its potent insulinotropic action, did not increase glucose elimination (11) . Although the mechanism of this action remains to be elucidated, the inhibition of insulin sensitivity by PACAP was thought to be mediated by adrenaline, which is released by PACAP from the adrenal medulla and is known to inhibit insulin action. In our study, the absence of any effect of PACAP on glucose disposal was also observed in wild-type mice, and the peptide was found to induce glucose intolerance in PAC1 -/-mice. This suggests that under in vivo conditions, PACAP counteracts the action of insulin on glucose elimination. The induction of glucose intolerance by PACAP in PAC1 -/-mice may therefore result not only from the defect of the insulinotropic action of the peptide, but also from VPAC receptor activation stimulating glucagon release from pancreatic A cells (8) and hepatic glycogenolysis (35, 36) , actions that counteract those of insulin. This is supported by the fact that VIP did not improve glucose tolerance despite its insulinotropic action, preserved in PAC1 -/-mice. However, it must be noted that PACAP was unable to increase plasma glucagon in the presence of high glucose levels during a glucose tolerance test (11) . Taken together, these data support the view that PACAP, by activating either PAC1 or VPAC receptors, in addition to its insulinotropic action, could also regulate glucose homeostasis in a complex manner that remains to be fully elucidated.
The impaired insulin secretion and glucose tolerance in PAC1 -/-mice that was recorded after gastric administration of glucose emphasize the physiological importance of the PAC1 receptor for insulin secretion and glycemia control, and suggest its involvement during food intake. This supports a recent demonstration that the PACAP receptor antagonist, PACAP , inhibits the insulin response to gastric glucose in mice (37) , and further suggests that this action is in part mediated by PAC1 receptors. It is known that during the cephalic and intestinal phases of food intake, the parasympathetic nerves supplying pancreatic islets participate in prandial insulin secretion (38) . Because PACAP is known to be localized in the islet parasympathetic nerves (15) and released during vagus stimulation (39), our findings suggest that this neuropeptide, through PAC1 receptor activation, could be involved in the parasympathetic control of insulin secretion during food intake.
In conclusion, our data demonstrate, under physiological conditions, that PAC1 receptors are (a) responsible for the insulinotropic action of PACAP in addition to VPAC receptors; (b) involved in the glucose competence of pancreatic β cells; and (c) participate in the control of glucose homeostasis, notably during food intake. PAC1 -/-mice should therefore represent an animal model that may be used to precisely determine the pharmacological role of this family of PACAP/VIP receptors in the regulation of insulin secretion and glucose homeostasis. Furthermore, this may be particularly useful for predicting specific drug actions. Because PACAP is present in pancreas and stimulates insulin secretion in humans (12) , it is tempting to speculate that a dysfunction of the PAC1 receptor, associated with a defect of glucose-stimulated insulin secretion and glucose intolerance, may be relevant to the development of the pathogenesis in human noninsulin-dependent diabetes mellitus.
